Healthequity (HQY) Cost of Revenue (2013 - 2026)

Healthequity's Cost of Revenue history runs 14 years deep, the most recent figure standing at $26.8 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 3.27% year-over-year to $26.8 million; the TTM figure through Apr 2026 stood at $169.4 million (up 391.64% YoY), while the FY2026 annual figure was $95.2 million, up 4.96% from the prior year.
• Cost of Revenue was $26.8 million for Q2 2026 at Healthequity, up from $24.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $103.4 million in Q4 2024 to a low of -$209.0 million in Q1 2025.
• Historically, Cost of Revenue has averaged $54.6 million across 5 years, with a median of $89.4 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue surged 625.62% in 2022, then tumbled 310.97% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $88.8 million in 2022, then grew by 1.43% to $90.0 million in 2023, then increased by 14.85% to $103.4 million in 2024, then tumbled by 76.39% to $24.4 million in 2025, then gained by 9.92% to $26.8 million in 2026.
• The last three Cost of Revenue figures came in at $26.8 million (Q2 2026), $24.9 million (Q1 2026), and $24.4 million (Q4 2025), per Business Quant data.